JP2015530867A - 抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法 - Google Patents

抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法 Download PDF

Info

Publication number
JP2015530867A
JP2015530867A JP2015517471A JP2015517471A JP2015530867A JP 2015530867 A JP2015530867 A JP 2015530867A JP 2015517471 A JP2015517471 A JP 2015517471A JP 2015517471 A JP2015517471 A JP 2015517471A JP 2015530867 A JP2015530867 A JP 2015530867A
Authority
JP
Japan
Prior art keywords
seq
antibody
hvr
amino acid
pcsk9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530867A5 (cg-RX-API-DMAC7.html
Inventor
イェン ウー，
イェン ウー，
セシリア プイ チー チウ，
セシリア プイ チー チウ，
ダニエル ケー． キルヒホーファー，
ダニエル ケー． キルヒホーファー，
アンドリュー ピーターソン，
アンドリュー ピーターソン，
ガネーシュ， エー． コルマム，
ガネーシュ， エー． コルマム，
モニカ コング ベルトラン，
モニカ コング ベルトラン，
ポール モラン，
ポール モラン，
ウェイ リー，
ウェイ リー，
ザンジー ラム，
ザンジー ラム，
リン ルイス，
リン ルイス，
アダ ヒュイ，
アダ ヒュイ，
ホイットモア ティングリー，
ホイットモア ティングリー，
ジョン ダグラス デイヴィス，
ジョン ダグラス デイヴィス，
ナーゲーシュワル アール． ブッダ，
ナーゲーシュワル アール． ブッダ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2015530867A publication Critical patent/JP2015530867A/ja
Publication of JP2015530867A5 publication Critical patent/JP2015530867A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015517471A 2012-06-15 2013-06-14 抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法 Pending JP2015530867A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261660605P 2012-06-15 2012-06-15
US61/660,605 2012-06-15
US201361786280P 2013-03-14 2013-03-14
US61/786,280 2013-03-14
PCT/US2013/046032 WO2013188855A1 (en) 2012-06-15 2013-06-14 Anti-pcsk9 antibodies, formulations, dosing, and methods of use

Publications (2)

Publication Number Publication Date
JP2015530867A true JP2015530867A (ja) 2015-10-29
JP2015530867A5 JP2015530867A5 (cg-RX-API-DMAC7.html) 2016-08-04

Family

ID=48746111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517471A Pending JP2015530867A (ja) 2012-06-15 2013-06-14 抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法

Country Status (13)

Country Link
US (2) US9266961B2 (cg-RX-API-DMAC7.html)
EP (1) EP2861624A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015530867A (cg-RX-API-DMAC7.html)
KR (1) KR20150023711A (cg-RX-API-DMAC7.html)
CN (1) CN104364266A (cg-RX-API-DMAC7.html)
AR (1) AR091462A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014031310A2 (cg-RX-API-DMAC7.html)
CA (1) CA2875096A1 (cg-RX-API-DMAC7.html)
HK (1) HK1205141A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014014830A (cg-RX-API-DMAC7.html)
RU (1) RU2015101113A (cg-RX-API-DMAC7.html)
TW (1) TW201410706A (cg-RX-API-DMAC7.html)
WO (1) WO2013188855A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500411A (ja) * 2015-11-27 2019-01-10 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｐｃｓｋ９抗体およびその使用
JP2019509254A (ja) * 2015-12-31 2019-04-04 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
JP2019518472A (ja) * 2016-04-07 2019-07-04 ▲邁▼博斯（香港）科技有限公司 プロタンパク質転換酵素サブチリシンケキシン９型の結合タンパク質及びその使用
JP2019523235A (ja) * 2016-06-24 2019-08-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 心血管疾患を治療するための組成物及び方法
JP2019527562A (ja) * 2016-06-08 2019-10-03 常州博嘉生物医▲薬▼科技有限公司 長時間作用性ｐｃｓｋ９特異的結合タンパク質及びその応用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
JP2017525680A (ja) * 2014-07-14 2017-09-07 アムジェン インコーポレイテッド 結晶性抗体製剤
CN105461809B (zh) * 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
WO2017118307A1 (zh) * 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
EP3515949A4 (en) * 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
CN107698680B (zh) * 2017-01-22 2019-03-01 北京东方百泰生物科技有限公司 抗pcsk9单克隆抗体
US11325945B2 (en) 2017-04-12 2022-05-10 Cadila Healthcare Limited Peptide based PCSK9 vaccine
CN107177003A (zh) * 2017-06-27 2017-09-19 上海海玫生物科技有限公司 一种特异性抗人pcsk9的抗体及其应用
TWI720325B (zh) 2017-06-30 2021-03-01 大陸商江蘇恒瑞醫藥股份有限公司 一種pcsk-9抗體醫藥組成物及其用途
GB201820687D0 (en) * 2018-12-19 2019-01-30 Kymab Ltd Antagonists
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
CN109776680B (zh) * 2019-01-25 2020-05-12 浙江蓝盾药业有限公司 抗人pcsk9单克隆抗体及其用途
US12264366B2 (en) 2019-05-17 2025-04-01 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
MX2023000002A (es) * 2020-07-02 2023-03-03 Biolojic Design Ltd Anticuerpos anti-receptor del factor de necrosis tumoral (tnfr2) y usos de los mismos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072263A1 (en) * 2009-12-11 2011-06-16 Irm Llc Pcsk9 antagonists
JP2012511913A (ja) * 2008-12-15 2012-05-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｃｓｋ９に対する高親和性ヒト抗体

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4444874A (en) 1982-09-15 1984-04-24 Eastman Kodak Company Photographic elements containing direct-positive emulsions and processes for their use
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20110230392A1 (en) 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
NZ518764A (en) 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU2001241461A1 (en) 2000-02-07 2001-08-14 Millennium Pharmaceuticals, Inc. Narc-1, novel subtilase-like homologs
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001269836A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
AU2002227280A1 (en) 2000-12-08 2002-06-18 Incyte Genomics, Inc. Protein modification and maintenance molecules
HUP0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING ANTIBODY COMPOSITION
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2374817B1 (en) 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20050114934A1 (en) 2005-01-31 2005-05-26 Pioneer Hi-Bred International , Inc. Soybean variety XB12K05
US20090130691A1 (en) 2005-09-16 2009-05-21 Institut De Recherches Cliniques De Montreal Screening proteinase modulators using a chimeric protein and ski-i proprotein convertase substrates and inhibitors
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2900402C (en) 2006-05-08 2018-01-16 Adaerata, Limited Partnership Pcsk9 polypeptide, ligand to said polypeptide, kits and methods using said ligands
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
EP2106261A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US20100041102A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
WO2008057457A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US8084437B2 (en) 2006-11-27 2011-12-27 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008109871A2 (en) 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
CA2681428A1 (en) 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2603615A1 (en) 2007-09-21 2009-03-21 Patrick Labonte Methods of reducing viral infection and kits therefore
SG2013014352A (en) * 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
AU2009241591A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of DSRNA targeting the PCSK9 gene
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
MX341286B (es) 2009-06-09 2016-08-12 Mitsubishi Gas Chemical Co Composicion de resina de poliamida y roducto moldeado.
EP2493505A4 (en) 2009-10-30 2013-06-12 Merck Sharp & Dohme Ax1 and ax189 pcsk9 antagonists and variants
CA2777542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
WO2012101252A2 (en) 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511913A (ja) * 2008-12-15 2012-05-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｃｓｋ９に対する高親和性ヒト抗体
WO2011072263A1 (en) * 2009-12-11 2011-06-16 Irm Llc Pcsk9 antagonists

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500411A (ja) * 2015-11-27 2019-01-10 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｐｃｓｋ９抗体およびその使用
JP2020127411A (ja) * 2015-11-27 2020-08-27 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｐｃｓｋ９抗体およびその使用
US10858447B2 (en) 2015-11-27 2020-12-08 Junshi Biosciences Co., Ltd. Anti-PCSK9 antibody and use thereof
JP7112659B2 (ja) 2015-11-27 2022-08-04 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｐｃｓｋ９抗体およびその使用
JP2019509254A (ja) * 2015-12-31 2019-04-04 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
JP7032662B2 (ja) 2015-12-31 2022-03-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
JP2019518472A (ja) * 2016-04-07 2019-07-04 ▲邁▼博斯（香港）科技有限公司 プロタンパク質転換酵素サブチリシンケキシン９型の結合タンパク質及びその使用
JP2019527562A (ja) * 2016-06-08 2019-10-03 常州博嘉生物医▲薬▼科技有限公司 長時間作用性ｐｃｓｋ９特異的結合タンパク質及びその応用
JP2019523235A (ja) * 2016-06-24 2019-08-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 心血管疾患を治療するための組成物及び方法
JP7110124B2 (ja) 2016-06-24 2022-08-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 心血管疾患を治療するための組成物及び方法

Also Published As

Publication number Publication date
US20160355606A1 (en) 2016-12-08
RU2015101113A (ru) 2016-08-10
AR091462A1 (es) 2015-02-04
CA2875096A1 (en) 2013-12-19
EP2861624A1 (en) 2015-04-22
WO2013188855A1 (en) 2013-12-19
HK1205141A1 (en) 2015-12-11
CN104364266A (zh) 2015-02-18
US9266961B2 (en) 2016-02-23
KR20150023711A (ko) 2015-03-05
US20130344085A1 (en) 2013-12-26
TW201410706A (zh) 2014-03-16
BR112014031310A2 (pt) 2017-07-25
MX2014014830A (es) 2015-05-11

Similar Documents

Publication Publication Date Title
US9266961B2 (en) Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US20240076388A1 (en) Fgfr1 agonists and methods of use
US11926674B2 (en) Anti-Jagged2 antibodies and methods of use
US20120195910A1 (en) Anti-pcsk9 antibodies and methods of use
TW201620932A (zh) 抗－ｂ型流感病毒血球凝集素抗體及其使用方法
MX2014008157A (es) Anticuerpos anti-lrp5 y metodos de uso.
JP2025186460A (ja) 種交差性抗潜在型ＴＧＦ－β１抗体および使用方法
JP2016507480A (ja) Ｒｏｎ組成物及びそれらの使用方法
NZ616206B2 (en) Fgfr1 agonists and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180116